Navigation Links
Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients
Date:4/28/2009

both groups.

Patients who experienced retrograde ejaculation and those who did not both showed significant improvement (p<.02) compared with patients receiving placebo in IPSS and Qmax after 12 weeks of treatment. Mean improvement in IPSS was greater in men experiencing this side effect than men who did not (-7.2 versus -6.1, p=0.3856) and for Qmax (3.1 mL versus 2.4 mL, p=0.0699).

About RAPAFLO(TM)

RAPAFLO(TM) is an effective, uniquely selective alpha-1 adrenergic receptor antagonist. RAPAFLO(TM) maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate. The antagonism of these receptors cause the smooth muscles in these tissues to relax and results in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alpha (1B) receptors that cause smooth muscle in peripheral vessels is significantly lower, which may minimize orthostatic hypotension.

The most common drug-related side effect was retrograde ejaculation. The second most commonly-reported adverse event was dizziness. The incidence of treatment-related dizziness was low and only slightly higher among RAPAFLO(TM) than placebo-treated patients (11 vs. 3 patients).

Previously presented data included information that in clinical trials RAPAFLO(TM) was administered with a single dose of medications for erectile dysfunction in healthy male subjects (N=24) and that there were no reported events of symptomatic orthostatis or dizziness. RAPAFLO(TM) demonstrated no meaningful electro cardiac effects during Phase 3 trials and during thorough QTc testing as required for new chemical entities by the FDA.

RAPAFLO(TM) was originally developed by Kissei Pharmaceutical Co., Ltd. in Japan, where RAPAFLO(TM) is the BPH market leader, and licensed to Watson for the U.S., Canada and Mexico markets. '/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. New Data Presented at AUAs Annual Conference Prove GELNIQUE(TM) (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
2. NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
3. Mersanas Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
4. Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009
5. 2009 ESCEO-IOF Alliance for Better Bone Health Young Investigator Award presented to Dr. Nick Harvey
6. IADR Oral Medicine and Pathology Research Award presented to UCLA professor
7. Prizes of the Grand Prix MSOO Award Presented in Moscow
8. Pasadena Marathon Presented By Kaiser Permanente Hails Partnership With Tiffany & Co.
9. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
10. Destination Fashion 2009 Presented by Stewart Rahr -
11. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 28, 2015 OsteoRemedies®, LLC, Memphis, ... two-stage revision of infected hip and knee arthroplasty. ... as a pre-formed, pre-loaded spacer with Gentamicin Antibiotics, ... joint space. Combined with a consistent process ... spacer is approved for temporary use for up ...
(Date:4/28/2015)... CA (PRWEB) April 28, 2015 Once considered ... Grow Lights have taken the industry by storm with perfectly ... to use unit. , More than half of ... KIND LED , proving the stigma is gone and ... The overwhelming positive response from customers and their first hand ...
(Date:4/28/2015)... 2015 Jovium®, a brand focused on ... better emotional balance, has begun to increase its market ... scale to enhance their mood and relieve some of ... Jovium® System aims to help patients overcome some of ... through all-natural products that do not cause or carry ...
(Date:4/28/2015)... NV (PRWEB) April 28, 2015 According ... Center for Ethics (June 27, 2014), prescription drugs ... world. Medical Science is becoming increasingly aware of the ... the market, such as chemotherapy drugs to treat cancer, ... that are quickly evolving to become increasingly resistant to ...
(Date:4/28/2015)... Foot and Ankle Specialists of ... Palmer ( Annapolis and Clarksville Divisions ) was ... the Maryland Podiatric Medical Association meeting on April 15, ... in 1992 with a Bachelor of Arts in Life ... intercollegiate soccer, track and cross-country. He then attended the ...
Breaking Medicine News(10 mins):Health News:SuperCloset Reports Surge in KIND LED Grow Light Sales, Saving Indoor Growing Enthusiasts up to 40% on their Power Usage. 2Health News:Jovium® Products Help Customers to Achieve Emotional Balance 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 3Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 4Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2
... , , CUPERTINO, Calif., July ... that Matthew Hogan, Chief Financial Officer, will be presenting at the ... August 5 at 4:00 pm Eastern Time. The conference is ... A webcast of the presentation will be accessible at: ...
... , WASHINGTON, July 28 The ... House of Representatives, goal of expanding health coverage to a ... the Society urges the House to make significant revisions to ... care its first priority and protect patient access to specialists. ...
... FRANKLIN LAKES, N.J., July 28 The Board of Directors ... a quarterly dividend of 33 cents per common share, payable on September ... annual dividend rate is $1.32 per share. , , ... technology company that develops, manufactures and sells medical devices, instrument systems and ...
... , MORRISTOWN, N.J., July 28 Watson Pharmaceuticals, ... and specialty branded pharmaceuticals, today announced a license agreement with ... generic version of Ferrlecit (sodium ferric gluconate complex in sucrose ... anemia in hemodialysis patients receiving supplemental epoetin therapy. , ...
... , , Hoag Hospital recognized ... providing optimal level care to breastfeeding mothers and infants , ... Memorial Hospital Presbyterian announced today its designation as a certified Baby-Friendly ... World Health Organization (WHO) and the United Nations Children,s Fund (UNICEF). ...
... PHILADELPHIA Cancer researchers are turning to mathematical models ... paper in Cancer Research , a journal of ... technique may answer questions about Herceptin resistance. ... Oncology Program at the University of Michigan Comprehensive Cancer ...
Cached Medicine News:Health News:DURECT to Present at the BMO Capital Markets Healthcare Conference 2Health News:SCAI Opposes U.S. House of Representatives Health Reform Bill in Current Form 2Health News:SCAI Opposes U.S. House of Representatives Health Reform Bill in Current Form 3Health News:Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R) 2Health News:Hoag Hospital Certified as Baby-Friendly Facility 2Health News:Hoag Hospital Certified as Baby-Friendly Facility 3Health News:Mathematical modeling predicts response to Herceptin 2
(Date:4/28/2015)... N.J. , April 28, 2015 As ... Stryker Orthopaedics, is kicking off tournament week by heading ... second consecutive year appearing at the tournament, Stryker continues ... about the importance of joint health and mobility. As ... , Stryker is bringing new features to enhance ...
(Date:4/28/2015)... April 28, 2015   HX360 today ... of the inaugural HX360 Innovation Challenge ... improved patient experience in hospital and health system ... original field of eighty-three entries, with the four ... panel during the HX360 Innovation Challenge program at ...
(Date:4/28/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... I am very excited to announce that we ... clinical trial for oral insulin (ORMD-0801) and the treatment of ... in the coming weeks. This clinical trial will be our largest ... milestone for the company, literally putting us in a different ...
Breaking Medicine Technology:The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 2The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 3The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 4Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 2Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 3Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 2Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 3
... Aug. 2 Cytokine PharmaSciences,Inc. (CPSI) today ... inhibitors showed oral efficacy in animal models. ... it is advancing one of these compounds,into ... or MIF, is linked to many,conditions, including ...
... ARBOR, Mich., Aug. 3 Far more of today,s,heart attack ... clogged heart arteries than even a,decade ago, a new study ... from this urgent treatment,-- which is known to save lives ... it at all, the study shows. And the chance ...
Cached Medicine Technology:Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors 2Many Heart Attack Patients Don't Get Best Emergency Treatment 2Many Heart Attack Patients Don't Get Best Emergency Treatment 3Many Heart Attack Patients Don't Get Best Emergency Treatment 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: